Clinical trials for professionals

This study is composed of 2 parts, part A and part B. The main objective of part A is to confirm whether the combination of the study drug with pembrolizumab is well tolerated and safe, and whether it helps treat people with CCECC. The main objective of Part B is to evaluate whether the combination of the study drug with pembrolizumab works better to treat people with CCECC than pembrolizumab alone.

The purpose of this study is to show whether giving chemotherapy before surgery also reduces the risk of tumor recurrence for colon tumors.

The purpose of the study is to test two different dosing schedules of venetoclax . 800 mg venetoclax in combination with polatuzumab vedotin and R-CHP for 5 days and 800 mg venetoclax in combination with polatuzumab vedotin and R-CHP for 10 days . to determine if the combination of the study drugs (also called the study treatment) is tolerated and to understand how your body processes the study treatment. The dose and dosing schedule of polatuzumab vedotin and R-CHP will always be the same.

The aim of this study is to test the safety and tolerability of monotherapy and combination therapy, to find out what effects, if any, these therapies have on people and their cancer and to select the safe and tolerable dose of INCB106385 to be studied further as monotherapy or combination therapy.

The main goal of this trial is to test the safety of the MCLA-128 trial drug in patients with solid (epithelial-type) tumors like yours and to see what effects it has on patients and their cancer.

The main objective of this study is to find out how well Debio 1143 works and how safe it is compared to a placebo. A placebo is an inactive substance that looks like the study drug, but does not contain any active drug. Researchers use a placebo to see if the study drug works better or if it is as safe as taking nothing.

The aim of the trial is to get your own white blood cells to attack all those cells that express a protein called CD19 that is present on tumor cells. These modifications will be made in the laboratory and will alter the genes of your T lymphocytes. Once the cells, which we will call ARI-0001, have been modified, they will be infused into your vein. The purpose of this study is to determine if these ARI-0001 cells are safe and effective in eradicating the disease.

The purpose of this additional pharmacogenomic research is to collect DNA and RNA samples for potential research that may help determine susceptibility to primary immune thrombocytopenia (PIT) and/or response to treatment with rozanolixizumab or drugs of that type in the main study.